From Clinical Trials to Clinical Practice – Incorporating Screening and Assessment Strategies for the Early Diagnosis of Alzheimer Disease

CME: 1.0

Target Audience

This educational activity is directed toward geriatricians, geriatric psychiatrists, and neurologists. Memory/dementia-care specialists, primary care physicians, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with AD will also be invited to participate.

Activity Overview

Early detection and accurate diagnosis of Alzheimer disease (AD) is crucial to slow or stop disease progression and preserve brain function. There may also be an early therapeutic window, either at the moderate cognitive impairment (MCI) stage or the proposed clinical stage. Practical screening measures that are brief, validated, and capable of differentiating MCI and dementia are needed, given the growing proportion of elderly individuals and their caregivers seeking medical help for memory-related changes. In this activity, experts in AD will review the available screening and assessment tools for patients with AD and review the patient groups who should be screened for AD. Participants will also learn about applying the screening tools for AD in current practice and in ongoing clinical trials.

This educational activity is an archive of the live symposium held on September 24, 2022.

Learning Objectives

Upon completion of this activity, participants should be better able to:
  • Describe the differences between available screening and assessment tools for patients with Alzheimer disease
  • Identify the role of screening and assessment tools in clinical trials for Alzheimer disease
  • Apply screening tools for Alzheimer disease in appropriate patient groups

Post a comment to this article